SHINE Technologies Awarded $32M by DOE/NNSA to Support Production of Molybdenum-99
Summary
The funding was added to DOE/NNSAs existing cooperative agreement with SHINE as part of the agencys efforts to help establish a reliable, U.S.-produced supply of molybdenum99 (Mo-99), the most commonly used medical isotope, without the use of highly enriched uranium. Upon its completion, Chrysalis will provide a sustainable, reliable source of Mo-99 for the U.S. and satisfy more than one-third of the worlds demand.Current Mo-99 production is limited to only a handful of government-owned nuclear research reactors located abroad. "We are very grateful for the DOE and NNSAs continued support to advance the domestic production of Mo-99, a critical medical isotope," said Greg Piefer, founder and CEO of SHINE. Anticipating further advancements, the companys forward-looking vision includes the creation of molybdenum-99, a diagnostic tool that plays a pivotal role in medical procedures aimed at detecting heart disease and cancer, as well as other isotopes used to diagnose and treat disease.SHINEs commitment to innovation extends beyond the realms of industry and healthcare. With a comprehensive and visionary approach, SHINE is steadfastly driving advancements across multiple sectors, leaving an indelible mark on the domains of technology, healthcare, and sustainable energy solutions.